Dreyer Verena J, Shi Jia-Xin, Rose Michael, Onyuro Maureen T, Steib Florian, Hilgers Lars, Seillier Lancelot, Dietrich Jana, Riese Janik, Meurer Steffen K, Weiskirchen Ralf, Neumann Ulf, Heij Lara, Luedde Tom, Loosen Sven H, Lurje Isabella, Lurje Georg, Gaisa Nadine T, Jonigk Danny, Bednarsch Jan, Dahl Edgar, Brüchle Nadina Ortiz
Institute of Pathology, Medical Faculty, RWTH Aachen University, 52074 Aachen, Germany.
Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), 52074 Aachen, Germany.
Cancers (Basel). 2024 Oct 29;16(21):3647. doi: 10.3390/cancers16213647.
: Cholangiocarcinoma (CCA) are aggressive bile duct cancers with a poor prognosis for which there are only few established prognostic biomarkers and molecular targets available. The gene , a known class II tumor suppressor gene (C2TSG), encodes a secreted protein of the extracellular matrix mediating tumor suppressive properties. Recently, it was surprisingly found that the ITIH5 protein is specifically upregulated in CCAs and that ITIH5 detection in blood could be an excellent liquid biopsy marker for indicating the presence of a CCA tumor in a patient. We therefore investigated whether patients with CCAs with abundant versus low ITIH5 protein expression also differ in their prognosis. : To clarify this question, a large CCA cohort (n = 175) was examined using immunohistochemistry on a tissue microarray (TMA). : Abundant ITIH5 expression in CCA was associated with favorable survival, a low UICC stage and the absence of perineural invasion (PNI). : ITIH5 has biomarker potential not only for the early detection of CCA from blood-based liquid biopsies but also as a prognostic tissue biomarker for risk stratification. Our results suggest that the upregulation of ITIH5 is particularly abundant in intrahepatic CCAs (iCCA). The mechanisms mediating the strong initial upregulation of ITIH5 during the oncogenic transformation of bile duct cells are still unclear.
胆管癌(CCA)是侵袭性胆管癌,预后较差,目前仅有少数已确立的预后生物标志物和分子靶点。ITIH5基因是一种已知的II类肿瘤抑制基因(C2TSG),编码一种介导肿瘤抑制特性的细胞外基质分泌蛋白。最近,令人惊讶地发现,ITIH5蛋白在CCA中特异性上调,并且血液中ITIH5的检测可能是用于指示患者体内CCA肿瘤存在的一种出色的液体活检标志物。因此,我们研究了ITIH5蛋白表达丰富与低表达的CCA患者在预后方面是否也存在差异。为了阐明这个问题 使用组织微阵列(TMA)对一个大型CCA队列(n = 175)进行了免疫组织化学检查。CCA中ITIH5的丰富表达与良好的生存率、低UICC分期以及无神经周围侵犯(PNI)相关。ITIH5不仅具有从基于血液的液体活检中早期检测CCA的生物标志物潜力,还具有作为用于风险分层的预后组织生物标志物的潜力。我们的结果表明,ITIH5的上调在肝内CCA(iCCA)中尤为丰富。在胆管细胞致癌转化过程中介导ITIH5强烈初始上调的机制仍不清楚。